Overview · Filed: —
UPC_APP_67755/2024
TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS
Procedural & sub-applicationsWithdrawal ApplicationsDusseldorf LDApplication Rop 265—Settled at: Pre-merits
Parties
Claimants
- Dexcom Inc.(Dexcom Group)
Reps: Markus Grosch (Quinn Emanuel); Johannes Bukow (Quinn Emanuel); Jan Axtmann (Quinn Emanuel); Paul Lehmann (Quinn Emanuel)
Respondents
- Abbott Laboratories(Abbott Group)
- Abbott Diabetes Care Inc.(Abbott Group)
- Abbott GmbH(Abbott Group)
- Abbott Diagnostics GmbH(Abbott Group)
- Abbott Laboratories GmbH(Abbott Group)
- Abbott Logistics B.V.(Abbott Group)
- Abbott France (S.A.S.)(Abbott Group)
- Abbott s.r.l.(Abbott Group)
- Abbott Gesellschaft m.b.H.(Abbott Group)
- Abbott B.V.(Abbott Group)
- Abbott (S.A./N.V.)(Abbott Group)
- Abbott Scandinavia Aktiebolag(Abbott Group)
- Abbott Oy(Abbott Group)
Judges
- Ronny ThomasPresiding judge
- Anna Bérénice Dr. ThomLegally qualified judge
- Petri RinkinenLegally qualified judge
- Claus ElmerosTechnically qualified judge
Patents
- EP4026488
CPC codes: A61B5/6849, A61B2560/063, A61B5/14865, A61B5/688, A61B5/14532, A61B5/14546, A61B5/6848, A61B5/6832, A61B5/68335, A61B2562/222, A61B2562/227, A61B2560/045…
Sector: Pharmaceutical & Medical
Outcome
Withdrawn
Filed: —
First decided: Jan 7, 2025
Language: —
Settled at: Pre-merits — settled commercially
Düsseldorf Local Division decision allowing the withdrawal of DexCom's infringement action (including application to amend the patent) and Abbott's counterclaim for revocation by mutual consent (R. 265 RoP). Following an out-of-court settlement, DexCom agreed to withdraw the infringement action and Abbott agreed to withdraw the revocation counterclaim. Neither party requested a costs decision. The oral hearing scheduled for 8 May 2025 was cancelled. Court fees reimbursed: DexCom receives 60% of infringement action fees (EUR 22,200), Abbott receives 60% of revocation counterclaim fees (EUR 12,000).